Literature DB >> 15188443

Down syndrome mouse models Ts65Dn, Ts1Cje, and Ms1Cje/Ts65Dn exhibit variable severity of cerebellar phenotypes.

L E Olson1, R J Roper, L L Baxter, E J Carlson, C J Epstein, R H Reeves.   

Abstract

Two mouse models are widely used for Down syndrome (DS) research. The Ts65Dn mouse carries a small chromosome derived primarily from mouse chromosome 16, causing dosage imbalance for approximately half of human chromosome 21 orthologs. These mice have cerebellar pathology with direct parallels to DS. The Ts1Cje mouse, containing a translocated chromosome 16, is at dosage imbalance for 67% of the genes triplicated in Ts65Dn. We quantified cerebellar volume and granule cell and Purkinje cell density in Ts1Cje. Cerebellar volume was significantly affected to the same degree in Ts1Cje and Ts65Dn, despite that Ts1Cje has fewer triplicated genes. However, dosage imbalance in Ts1Cje had little effect on granule cell and Purkinje cell density. Several mice with dosage imbalance for the segment of the Ts65Dn chromosome not triplicated in Ts1Cje had phenotypes that contrasted with those in Ts1Cje. These observations do not readily differentiate between two prevalent hypotheses for gene action in DS. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15188443     DOI: 10.1002/dvdy.20079

Source DB:  PubMed          Journal:  Dev Dyn        ISSN: 1058-8388            Impact factor:   3.780


  64 in total

Review 1.  Trisomy 21 and early brain development.

Authors:  Tarik F Haydar; Roger H Reeves
Journal:  Trends Neurosci       Date:  2011-12-09       Impact factor: 13.837

2.  Defective cerebellar response to mitogenic Hedgehog signaling in Down [corrected] syndrome mice.

Authors:  Randall J Roper; Laura L Baxter; Nidhi G Saran; Donna K Klinedinst; Philip A Beachy; Roger H Reeves
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

3.  Hedgehog agonist therapy corrects structural and cognitive deficits in a Down syndrome mouse model.

Authors:  Ishita Das; Joo-Min Park; Jung H Shin; Soo Kyeong Jeon; Hernan Lorenzi; David J Linden; Paul F Worley; Roger H Reeves
Journal:  Sci Transl Med       Date:  2013-09-04       Impact factor: 17.956

Review 4.  Neurotrophin Signaling and Stem Cells-Implications for Neurodegenerative Diseases and Stem Cell Therapy.

Authors:  Subrata Pramanik; Yanuar Alan Sulistio; Klaus Heese
Journal:  Mol Neurobiol       Date:  2016-11-05       Impact factor: 5.590

5.  The fetal brain transcriptome and neonatal behavioral phenotype in the Ts1Cje mouse model of Down syndrome.

Authors:  Faycal Guedj; Jeroen L A Pennings; Millie A Ferres; Leah C Graham; Heather C Wick; Klaus A Miczek; Donna K Slonim; Diana W Bianchi
Journal:  Am J Med Genet A       Date:  2015-05-14       Impact factor: 2.802

Review 6.  Down syndrome: the brain in trisomic mode.

Authors:  Mara Dierssen
Journal:  Nat Rev Neurosci       Date:  2012-12       Impact factor: 34.870

7.  Evidence that increased Kcnj6 gene dose is necessary for deficits in behavior and dentate gyrus synaptic plasticity in the Ts65Dn mouse model of Down syndrome.

Authors:  Alexander M Kleschevnikov; Jessica Yu; Jeesun Kim; Larisa V Lysenko; Zheng Zeng; Y Eugene Yu; William C Mobley
Journal:  Neurobiol Dis       Date:  2017-03-22       Impact factor: 5.996

8.  Environmental enrichment rescues postnatal neurogenesis defect in the male and female Ts65Dn mouse model of Down syndrome.

Authors:  Lina Chakrabarti; Joseph Scafidi; Vittorio Gallo; Tarik F Haydar
Journal:  Dev Neurosci       Date:  2011-08-25       Impact factor: 2.984

Review 9.  Mouse models for Down syndrome-associated developmental cognitive disabilities.

Authors:  Chunhong Liu; Pavel V Belichenko; Li Zhang; Dawei Fu; Alexander M Kleschevnikov; Antonio Baldini; Stylianos E Antonarakis; William C Mobley; Y Eugene Yu
Journal:  Dev Neurosci       Date:  2011-08-25       Impact factor: 2.984

10.  Normal protein composition of synapses in Ts65Dn mice: a mouse model of Down syndrome.

Authors:  Fabian Fernandez; Jonathan C Trinidad; Martina Blank; Dong-Dong Feng; Alma L Burlingame; Craig C Garner
Journal:  J Neurochem       Date:  2009-04-22       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.